List of Excipients in Branded Drug IBUPROFEN 200MG

« Back to Dashboard

Generic Drugs Containing IBUPROFEN 200MG

Company	Ingredient	NDC	Excipient
Athlete's Needs Inc	ibuprofen 200mg	53185-381	FD&C YELLOW NO. 6
Athlete's Needs Inc	ibuprofen 200mg	53185-381	HYPROMELLOSES
Athlete's Needs Inc	ibuprofen 200mg	53185-381	POLYDEXTROSE
Athlete's Needs Inc	ibuprofen 200mg	53185-381	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in IBUPROFEN 200MG?

# Of NDCs	Excipient
1	CARNAUBA WAX
4	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
1	FD&C BLUE NO. 2

Ibuprofen 200 mg Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 5, 2026

Ibuprofen 200 mg is a mature, low-cost OTC drug with no meaningful composition-of-matter exclusivity in the United States. Commercial value is concentrated in formulation performance, manufacturing cost, dosage-form convenience, private-label distribution, and differentiated consumer positioning. The strongest opportunities are rapid-dissolution tablets, softgels, pediatric liquids, chewables, low-sugar products, and cost-efficient contract manufacturing.

What is the FDA regulatory status of ibuprofen 200 mg?

Ibuprofen 200 mg is regulated in the United States as an OTC internal analgesic, antipyretic, and anti-inflammatory product under the FDA OTC monograph framework.

For conventional adult products, the principal regulatory parameters are:

Parameter	U.S. position
Active ingredient	Ibuprofen
Typical OTC strength	200 mg per unit dose
Indications	Temporary relief of minor aches and pains; reduction of fever
Population	Adults and children 12 years and older, subject to labeling
Typical dosing	200 mg every 4 to 6 hours; higher OTC doses subject to label limits
Maximum OTC daily dose	Generally 1,200 mg unless directed by a physician
Primary dosage forms	Tablets, caplets, capsules, softgels, chewables, oral suspensions
Regulatory pathway	OTC monograph compliance or approved application
Prescription approval requirement	Not required for a monograph-compliant OTC product
Biosimilar pathway	Not applicable

The FDA’s internal analgesic monograph establishes active-ingredient, indication, dosing, labeling, and safety requirements. A manufacturer using an approved OTC dosage form and compliant labeling generally does not need to rely on a prescription-drug ANDA pathway (FDA, 2023a; 21 C.F.R. Part 343).

The product must carry NSAID warnings addressing stomach bleeding, cardiovascular risk, allergic reactions, pregnancy-related restrictions, and interactions with other NSAIDs or anticoagulants. Excipient changes cannot create a misleading impression that the product is safer than conventional ibuprofen.

What excipients are used in ibuprofen 200 mg tablets?

Ibuprofen has low aqueous solubility and is a weak acid. Its dissolution behavior is affected by particle size, wetting, compression, disintegration, pH, and the presence of surfactants. The excipient system therefore has a direct effect on onset perception, tablet robustness, and manufacturing economics.

Common excipient functions include:

Function	Candidate excipient classes	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet weight, density, and compression
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Accelerates tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate, stearic acid	Supports ejection and prevents sticking
Glidant	Colloidal silicon dioxide	Improves powder flow
Surfactant or wetting agent	Sodium lauryl sulfate, polysorbates, poloxamers	Improves wetting and dissolution
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the core and improves swallowing
Taste masking	Sweeteners, flavors, polymer coatings, ion-exchange resins	Supports chewable and pediatric products
Suspending system	Xanthan gum, cellulose derivatives, bentonite, carbomers	Stabilizes liquid suspensions
Preservative	Sodium benzoate, parabens, potassium sorbate	Controls microbial growth in aqueous products

The final selection must comply with FDA inactive-ingredient requirements and the FDA Inactive Ingredient Database, including route, dosage form, and maximum potency considerations (FDA, 2023b).

Which excipient strategy is strongest for immediate-release ibuprofen?

The highest-value tablet strategy is a direct-compression or dry-granulation platform that achieves rapid disintegration without excessive manufacturing complexity.

A practical immediate-release platform can use:

• Microcrystalline cellulose or mannitol as the principal diluent.
• Crospovidone or croscarmellose sodium as the primary disintegrant.
• Colloidal silicon dioxide to improve flow.
• Magnesium stearate or sodium stearyl fumarate at a controlled concentration.
• A small quantity of surfactant where dissolution data show a meaningful benefit.
• A film coat that does not materially delay disintegration.

The main formulation trade-off is lubrication. Excess magnesium stearate can reduce tablet tensile strength and slow wetting. Excess binder can improve hardness while increasing disintegration time. High surfactant levels can affect taste, friability, and stability.

A formulation development program should compare:

1. Particle-size grades of ibuprofen.
2. Direct compression against wet or dry granulation.
3. Disintegrant type and concentration.
4. Lubricant concentration and blending time.
5. Surfactant inclusion versus a surfactant-free control.
6. Tablet hardness, friability, disintegration, dissolution, and stability.
7. Performance after accelerated storage.

The commercial target is not merely faster dissolution. The product must maintain acceptable tablet appearance, packaging stability, throughput, and cost per dose.

What formulations are protected by ibuprofen patents?

The original ibuprofen compound patents are expired. The foundational U.S. ibuprofen patent, U.S. Patent No. 3,385,886, was issued in 1968 and no longer creates a practical barrier to OTC manufacture (U.S. Patent No. 3,385,886).

IP category	Current commercial significance
Ibuprofen composition of matter	Expired
Basic 200 mg tablet	Generally open, subject to product-specific rights
Conventional excipient combinations	Usually difficult to protect broadly
Softgel delivery systems	Potentially protectable through formulation, shell, fill, or process claims
Liquid suspension systems	Potential protection for taste masking, sedimentation control, or preservative systems
Fast-dissolving products	Potential protection for particle engineering, granulation, or excipient ratios
Combination products	Potential method-of-use, formulation, or packaging protection
Manufacturing process	Potential protection for granulation, coating, encapsulation, or continuous processing
Trade dress and branding	Commercially important but separate from drug patent protection

A new ibuprofen product can have patentable features even though ibuprofen itself is off patent. The patent must generally rely on a technically defined formulation, process, delivery system, or use. Broad claims covering ordinary tablet excipients are vulnerable to validity and obviousness challenges.

The most defensible formulation claims typically require a measurable technical result, such as:

• A specified dissolution profile.
• A defined particle-size distribution.
• A particular ibuprofen-to-polymer or ibuprofen-to-surfactant ratio.
• Improved suspension stability.
• Reduced sedimentation or caking.
• Enhanced taste masking.
• A defined softgel fill composition.
• A manufacturing process that produces a specified solid-state form or release profile.

What is the Orange Book status of ibuprofen 200 mg?

Conventional OTC monograph ibuprofen products are not equivalent to prescription products listed in the FDA Orange Book. The Orange Book principally identifies approved prescription drug products, related patent listings, and exclusivity information. OTC monograph products generally do not depend on Orange Book listing for market access.

This has several consequences:

• A conventional OTC ibuprofen 200 mg launch does not usually involve an Orange Book Paragraph IV certification.
• There is no standard Orange Book patent-certification process for a monograph-compliant product.
• A manufacturer can enter through monograph compliance without challenging a branded NDA patent estate.
• Patents covering a proprietary formulation may still create litigation risk outside the basic monograph framework.
• Brand owners can rely on trademarks, packaging, distribution, and retailer relationships even when patent barriers are weak.

A product submitted under an approved application rather than solely under the OTC monograph could have a different regulatory and patent profile. That distinction must be assessed product by product.

When does ibuprofen 200 mg lose exclusivity?

Ibuprofen 200 mg has already lost core pharmaceutical exclusivity in the United States and most major markets. Generic and private-label manufacturers have long produced conventional tablets, capsules, and liquids.

The relevant commercial timeline is:

Event	Timing
Ibuprofen developed and commercialized	1960s
Foundational U.S. patent issued	1968
Core patent protection	Expired decades ago
OTC commercialization	Established market
Current market position	Commodity active ingredient with differentiated dosage forms
New product protection	Limited to formulation, process, use, packaging, or brand assets

There is no standard loss-of-exclusivity event remaining for the basic 200 mg molecule. The commercial question is whether a new product can create a defendable consumer or manufacturing advantage.

Which companies are challenging branded ibuprofen products?

Ibuprofen is not primarily a current Paragraph IV battleground. The market is supplied by established generic manufacturers, OTC brand owners, private-label distributors, and contract manufacturers.

Competitive groups include:

• Branded OTC companies selling Advil and related products.
• Generic manufacturers selling ibuprofen tablets, caplets, capsules, and suspensions.
• Retailers and pharmacy chains selling store-brand products.
• Contract development and manufacturing organizations producing private-label OTC products.
• Softgel specialists and consumer-health companies with differentiated delivery systems.

The main competitive pressure is price. A new entrant without a differentiated dosage form, strong retailer access, or manufacturing advantage is likely to compete against products with low customer-acquisition costs and established distribution.

What are the strongest commercial opportunities for ibuprofen excipients?

Rapid-dissolution tablets and caplets

Consumers often associate faster disintegration with faster relief, even when pharmacokinetic differences are modest. A rapid-dissolution product can command a premium if the dissolution advantage is reproducible and supported by compliant labeling.

The excipient opportunity is to improve wetting and disintegration while preserving:

• Tablet hardness.
• Low friability.
• High-speed press performance.
• Stability in high-humidity conditions.
• Acceptable taste after coating.

Softgels

Softgels remain commercially attractive because they are easy to swallow and can create a premium presentation. Their formulation may use ibuprofen dissolved or dispersed in a lipid or nonaqueous vehicle, subject to stability and fill-volume constraints.

Key development issues include:

• Ibuprofen solubility in the fill vehicle.
• Shell compatibility.
• Migration of fill components into the gelatin shell.
• Oxygen and moisture sensitivity.
• Leakage and brittleness.
• Manufacturing yield.

Softgel differentiation is more likely to support premium pricing than a conventional tablet, but capital requirements and manufacturing complexity are higher.

Pediatric oral suspension

Pediatric ibuprofen products can compete through taste, dosing accuracy, preservative strategy, and packaging. Excipient priorities include:

• Palatable flavor and sweetness.
• Uniform dose delivery after shaking.
• Low sedimentation and easy redispersion.
• Alcohol-free formulation.
• Appropriate preservative system.
• Child-resistant packaging with an accurate dosing syringe.

The principal technical risk is sedimentation or caking that produces nonuniform dosing. A suspension that requires prolonged shaking or forms a hard sediment is commercially weak.

Chewable and low-sugar products

Chewables can serve children and adults who have difficulty swallowing tablets. The excipient system must manage the bitter, acidic taste of ibuprofen without producing excessive tablet size or a gritty mouthfeel.

Sugar-free formulations can target diabetic consumers and consumers seeking lower-calorie products. Polyols such as sorbitol, mannitol, and xylitol can improve mouthfeel, but excessive polyol loading can cause gastrointestinal discomfort and alter compression behavior.

Sodium-free and excipient-conscious products

Some consumers and healthcare professionals seek products with reduced sodium, fewer dyes, no artificial flavors, or simplified excipient profiles. These claims must be precise. Removing a colorant or changing a sweetener is commercially useful only if the product remains stable, acceptable, and cost competitive.

How strong is the ibuprofen 200 mg patent estate?

The core estate is weak because the active ingredient and basic dosage form are long off patent. New patent strength depends on claim specificity and technical evidence.

Patent strategy	Relative strength
Ibuprofen plus ordinary tablet excipients	Low
Narrow dissolution or disintegration profile	Moderate if technically unexpected
Proprietary softgel fill and shell system	Moderate to strong if difficult to design around
Taste-masked pediatric suspension	Moderate
Novel particle engineering or solid-state form	Moderate, subject to prior art
Manufacturing process with measurable product advantage	Moderate
Broad “fast-acting ibuprofen” claims	Low unless supported by defined technical limitations
Packaging-only claims	Usually limited

Freedom-to-operate analysis should cover formulation patents, process patents, solid-state patents, softgel technology, taste-masking systems, and combination products in the target jurisdictions. Patent risk is generally lower for a conventional immediate-release tablet using established excipients than for a proprietary liquid, softgel, or modified delivery platform.

What generic launch risks exist for ibuprofen 200 mg?

A conventional ibuprofen 200 mg launch has low patent-entry risk but meaningful operational and regulatory risk.

The principal risks are:

1. Dissolution failure. Poor wetting, excessive lubrication, or inadequate disintegration can delay release.
2. Content uniformity. Low-dose unit operations can create blend segregation, particularly in high-throughput manufacturing.
3. Stability failure. Moisture, oxidation, coating defects, and packaging permeability can reduce shelf life.
4. Taste failure. Pediatric and chewable products are vulnerable to consumer rejection.
5. Labeling noncompliance. NSAID warnings, age restrictions, dosing instructions, and combination-product claims are tightly controlled.
6. Packaging failure. Child-resistant closures, dosing devices, blister integrity, and tamper evidence affect marketability.
7. Retailer price pressure. Private-label products can compress margins rapidly.
8. Supply-chain concentration. API and excipient sourcing can affect continuity and cost.
9. Product-liability exposure. NSAID safety concerns create litigation risk independent of patent status.

How does ibuprofen compare with acetaminophen in excipient strategy?

Ibuprofen and acetaminophen both compete in OTC pain and fever relief, but their formulation challenges differ.

Issue	Ibuprofen 200 mg	Acetaminophen
Drug class	NSAID	Analgesic and antipyretic
Key formulation issue	Low aqueous solubility and wetting	High-dose load and taste
Typical adult unit dose	200 mg OTC	325 mg or 500 mg
Premium dosage forms	Softgels, rapid-release tablets, suspensions	Caplets, liquids, chewables, combination products
Safety differentiation	GI, cardiovascular, renal, pregnancy warnings	Liver toxicity and maximum daily dose
Excipient focus	Dissolution, dispersion, suspension stability	Tablet size, taste masking, dose load
Patent opportunity	Delivery systems and formulation	Combination products, delivery systems, formulations

Ibuprofen offers more opportunity for excipient-driven dissolution differentiation. Acetaminophen offers more opportunity in high-dose tablet architecture, taste masking, and combination products.

Is biosimilar risk relevant to ibuprofen 200 mg?

No. Ibuprofen is a small-molecule active pharmaceutical ingredient, not a biologic. Biosimilar competition, reference-product exclusivity, and biologic patent dance procedures do not apply.

The relevant competitive categories are generic tablets, private-label OTC products, branded formulations, softgels, liquid suspensions, and combination products.

Key Takeaways

• Ibuprofen 200 mg has no meaningful remaining core patent exclusivity in the United States.
• OTC monograph compliance, rather than Orange Book patent certification, is the central U.S. regulatory pathway for conventional products.
• Excipient strategy should focus on dissolution, disintegration, taste, suspension stability, and manufacturing cost.
• The strongest commercial opportunities are rapid-release tablets, softgels, pediatric liquids, chewables, and low-sugar formulations.
• Broad formulation patents are difficult to defend; narrow claims tied to measurable technical performance are more credible.
• Conventional tablets face low patent risk but intense price and distribution competition.
• Biosimilar risk is irrelevant because ibuprofen is a small-molecule drug.
• Manufacturing efficiency, retailer access, packaging, and consumer usability are more important than molecule-level IP.

FAQs

Can a company launch an ibuprofen 200 mg private-label product without an ANDA?

Yes, a product that complies with the applicable OTC monograph, including active ingredient, dosage, indications, labeling, manufacturing, and quality requirements, may be marketed without relying on a conventional prescription-drug ANDA pathway.

Which excipient improves ibuprofen dissolution the most?

No single excipient is universally optimal. Crospovidone, croscarmellose sodium, surfactants, particle-size control, and improved wetting can each contribute. Performance depends on the complete formulation and manufacturing process.

Are ibuprofen softgels protected by patents?

Some softgel products may be covered by formulation, shell, fill, process, or delivery-system patents. Protection is product-specific and does not arise from ibuprofen’s expired compound patent.

What is the best ibuprofen dosage form for a premium OTC launch?

Softgels and rapid-release products generally provide the clearest premium positioning. Pediatric suspensions and chewables can also support differentiation when taste, dosing accuracy, or sugar reduction is demonstrably better.

Can a new ibuprofen formulation claim faster pain relief?

Only if the claim is supported by appropriate evidence and complies with FDA labeling and advertising requirements. Faster dissolution alone does not automatically establish faster clinical relief.

References

1. Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. U.S. Government Publishing Office.

2. U.S. Food and Drug Administration. (2023a). OTC Monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

3. U.S. Food and Drug Administration. (2023b). Inactive Ingredient Database. FDA.

4. U.S. Food and Drug Administration. (2024). Drug products marketed under the OTC monograph system. FDA.

5. U.S. Patent No. 3,385,886. (1968). Substituted phenyl propionic acids. U.S. Patent and Trademark Office.

6. DailyMed. (2024). Ibuprofen tablet, 200 mg: Consumer and professional labeling. National Library of Medicine.